Z. Berger

发表

Rapamycin alleviates toxicity of different aggregate-prone proteins.

D. Rubinsztein, B. Ravikumar, F. Menzies, 2006, Human molecular genetics.

Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.

D. Rubinsztein, J. Davies, Z. Berger, 2006, The international journal of biochemistry & cell biology.

Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy

K. Ashe, M. Hutton, Z. Wszolek, 2007, The Journal of Neuroscience.

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

Francesco Scaravilli, Douglas F Easton, Shouqing Luo, 2004, Nature Genetics.

Tool Compounds Robustly Increase Turnover of an Artificial Substrate by Glucocerebrosidase in Human Brain Lysates

Claude Ambroise, D. Riddell, Z. Berger, 2015, PloS one.

Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.

R. Kurumbail, B. L. Kormos, M. Hayward, 2015, Journal of medicinal chemistry.

Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons

Z. Berger, W. Hirst, K. Paumier, 2014, Journal of neurochemistry.

Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.

R. Kurumbail, B. L. Kormos, P. Verhoest, 2014, Bioorganic & medicinal chemistry letters.

Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

S. Melquist, D. Neary, B. Boeve, 2006, Nature.

Lithium induces autophagy by inhibiting inositol monophosphatase

D. Rubinsztein, S. Sarkar, L. Cook, 2005, The Journal of cell biology.

Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease

Z. Berger, S. J. Sukoff Rizzo, E. Kaftan, 2013, PloS one.

Dynein mutations impair autophagic clearance of aggregate-prone proteins

Steve D. M. Brown, D. Rubinsztein, B. Ravikumar, 2005, Nature Genetics.

Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway.

Claire H. Michel, D. Rubinsztein, M. Pasco, 2005, Human molecular genetics.

Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation.

Z. Berger, M. LaVoie, Kelsey A. Smith, 2010, Biochemistry.

Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion.

D. Rubinsztein, J. Davies, S. Luo, 2006, Human molecular genetics.

The roles of the ubiquitin-proteasome and autophagy–lysosome pathways in Huntington's disease and related conditions

D. Rubinsztein, B. Ravikumar, S. Sarkar, 2003, Clinical Neuroscience Research.

Rapamycin pre-treatment protects against apoptosis.

D. Rubinsztein, B. Ravikumar, C. Vacher, 2006, Human molecular genetics.

Human A53T α-Synuclein Causes Reversible Deficits in Mitochondrial Function and Dynamics in Primary Mouse Cortical Neurons

A. Milici, J. Schwartz, Z. Berger, 2013, PloS one.

Triplet repeat diseases: the role of fly models in understanding disease mechanisms and designing possible therapies.

Z. Berger, 2008, SEB experimental biology series.

Can the people in poor countries benefit from science

Z. Berger, 2003 .

J06 A randomized, double-blind, placebo-controlled phase ii efficacy and safety study of the PDE10A inhibitor PF-02545920 in huntington disease (amaryllis)

R. Reilmann, M. Delnomdedieu, Z. Berger, 2018, Clinical therapeutics.